Starpharma Holdings (ASX:SPL) FCF Margin %: 33.92% (As of Dec. 2025)

What is Starpharma Holdings FCF Margin %?

Starpharma Holdings ASX:SPL +0.72% 52 FCF Margin % is 33.92% as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 52/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Starpharma Holdings ranks better than 69.34% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Starpharma Holdings's Free Cash Flow for the six months ended in Dec. 2025 was A$3.67 Mil. Starpharma Holdings's Revenue for the six months ended in Dec. 2025 was A$10.83 Mil. Therefore, Starpharma Holdings's FCF Margin % for the quarter that ended in Dec. 2025 was 33.92%.

As of today, Starpharma Holdings's current FCF Yield % is -0.39%.

The historical rank and industry rank for Starpharma Holdings's FCF Margin % or its related term are showing as below:

ASX:SPL' s FCF Margin % Range Over the Past 10 Years
Min: -837.26 Med: -383.59 Max: -7.94
Current: -7.94

During the past 13 years, the highest FCF Margin % of Starpharma Holdings was -7.94%. The lowest was -837.26%. And the median was -383.59%.

ASX:SPL's FCF Margin % is ranked better than
69.34% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs ASX:SPL: -7.94

Starpharma Holdings FCF Margin % Related Terms

Starpharma Holdings FCF Margin % Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings FCF Margin % Chart

Starpharma Holdings Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

FCF Margin %

Get a 7-Day Free Trial

-837.26

-299.00

-481.59

-85.25

-138.46

Starpharma Holdings Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
FCF Margin %	Get a 7-Day Free Trial															29.03	-838.37	-107.36	-157.87	33.92

ASX:SPL vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Starpharma Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Starpharma Holdings FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's FCF Margin % falls into.

Save Embed

52GF Score

Starpharma Holdings Ltd ASX:SPL

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Starpharma Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Starpharma Holdings's FCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2025 )	/	Revenue (A: Jun. 2025 )
	=	-6.801	/	4.912
	=	-138.46 %

Starpharma Holdings's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	3.674	/	10.832
	=	33.92 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of 33.92% mean?

Starpharma Holdings (ASX:SPL) has a FCF Margin % of 33.92% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Starpharma Holdings and its competitors. According to the industry distribution chart, Starpharma Holdings ranks #294 out of 959 companies in the Biotechnology industry, placing it in the top 30.7%.

Is Starpharma Holdings' FCF Margin % too high?

Starpharma Holdings' current FCF Margin % is 33.92%. Based on the distribution chart, Starpharma Holdings ranks #294 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Starpharma Holdings has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Starpharma Holdings' FCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #294 out of 959 companies for FCF Margin %. This puts Starpharma Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current FCF Margin % is 33.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Starpharma Holdings stock overvalued right now?

Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current FCF Margin % is 33.92%. Starpharma Holdings' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current FCF Margin % is 33.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

FCF Margin %: 33.92%
GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:TTX ASX:OCC ASX:RCE ASX:ACW ASX:CUV ASX:RAC ASX:NYR ASX:ILA ASX:DXB ASX:ATH VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges SPHRY:USA SPHRF:USA PQ6:Germany

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067

Website https://www.starpharma.com

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.

52GF Score

Get the complete analysis for ASX:SPL

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.70

Price

A$0.43

GF Value

View ASX:SPL Analysis

See FCF Margin % data for all stocks →